ANIX - Anixa Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Anixa Biosciences, Inc.

3150 Almaden Expressway
Suite 250
San Jose, CA 95118
United States
408-708-9808
http://www.anixa.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Dr. Amit Kumar Ph.D.Chairman, Pres & CEO693.03kN/A1964
Mr. Michael J. CatelaniCOO, CFO & Corp. Sec.281.92kN/A1967
Mr. John RoopSr. VP of EngineeringN/AN/A1950
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Anixa Biosciences, Inc., a cancer-focused biotechnology company, develops both diagnostics and therapeutics to detect cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs, which genetically engineer a patient's own immune cells to fight cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Corporate Governance

Anixa Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.